Effect of Helicobacter pylori eradication on metabolic profile: an international, multicenter, case-control study

BMC Gastroenterology

Research

Siamak Baghaei¹  Pezhman Alavinejad¹  Eskandar Hajiani¹  Alireza Sedaghat¹  Azam Satari¹  Abazar Parsi¹  Samira Mohammadi¹  Seyed Jalal Hashemi¹  Mohammad Javad Rezaei¹  Masoud Arshadzadeh²  Quang Trung Tran³  Omid Eslami⁴  Ahmad Hormati⁵  Mohammed Hussien Ahmed⁶  Morteza Nayebi⁷ 

[1] Alimentary Tract Research Center, Imam Khomeini Hospital Clinical Research Development Unit, The School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran;Department of Gastroenterology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran;Department of Internal Medicine, University of Medicine and Pharmacy, Hue University, Hue, Vietnam;Gastroenterology and Hepatology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran;Gastrointestinal and Liver Diseases Research Center, Firouzgar Hospital, Iran University of Medical Sciences, Tehran, Iran;Lecturer Hepatology Gastroenterology and Infectious Diseases, Faculty of Medicine, Kafrelsheikh University, Cairo, Egypt;Shahid Rajaie Cardiovascular, Medical & Research Center, Iran University of Medical Sciences, Tehran, Iran;

关键词: Helicobacter pylori;    Metabolic profile;    Eradication;   

DOI  :  10.1186/s12876-022-02604-3

 received in 2022-07-03, accepted in 2022-12-02,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundAs a gram-negative and microaerophilic bacterium, Helicobacter pylori (HP) is the main cause of chronic gastritis. Therefore, considering the high prevalence of HP infection worldwide, as well as the increasing prevalence of metabolic disorders, the present study aimed to investigate the relationship between HP infection eradication and metabolic profile.MethodsThis prospective case-control study was performed on patients with HP infection whom referred to 7 medical centers in 3 countries (Iran, Egypt, and Vietnam) in 2020–2021. The metabolic profile of all of the participants evaluated before starting of treatment for HP eradication and 3 months after the treatment. Then changes of metabolic profile compared between those with successful HP eradication (group A) and subjects who failed to eradicate (group B).ResultsOverall, 199 patients, including 93 male (46.7%) with the mean age of 44.5 years (18–93 years) included. Based on response to treatment, the participants allocate into group A (those who respond to HP eradication): 164 cases (82.42%); or group B as those who failed to achieve eradication (35 cases, 17.58%). Racially 86.9% of participants were Caucasian and 89% diagnosed as non-ulcer dyspepsia (NUD). The most prevalent comorbidity include hypertension (11.5%) and hyperlipidemia (10%) which were more prevalent in group B (P = 0.002). Three months after therapy, average weight of participants among those who achieved eradication (group A) decreased from 73.1 to 71.4 kg (P = 0.01), but in comparison with group B, was non-significant (P = 0.171). The BMI of patients before and after treatment did not show any significant differences. The biochemical parameters of patients before and after treatment were not significantly different regardless of treatment success (P > 0.05). The levels of total cholesterol and VLDL cholesterol after treatment were not significantly different from baseline values in two groups. HDL and LDL cholesterol levels before and after treatment in the resistant group were significantly higher than the responding group. Average serum TG level decreased significantly after treatment in the group A (P < 0.0001), in contrast to the resistant group (P = 0.356). The liver transaminases (AST and ALT) before and after treatment were not significantly different between the two groups (P > 0.05). The results of logistic regression showed that the eradication of infection has no significant affect any of the metabolic profile parameters.ConclusionHP infection treatment in individuals without significant metabolic disorders does not affect metabolic parameters up to 3 months after eradication. HP eradication among subjects with several comorbidities mandates eradication protocol intensification to avoid treatment failure.

【 授权许可】

CC BY   
© The Author(s) 2022

【 图 表 】

12982_2022_119_Article_IEq87.gif